한글목차

개요

혈액 선별 검사는 오염된 혈액이나 혈액 성분이 임상용으로 유통되는 것을 막기 위해 감염 징후를 식별하기 위해 실시됩니다. 혈액 선별 검사는 질병의 증상이 없는 사람의 잠재적인 건강 장애 또는 질병을 감지하기 위해 수행됩니다.

혈액 선별 전략은 혈액 단위의 안전을 보장하기 위해 설계되었지만, 반응성 검사 결과를 헌혈자에게 알리는 데 사용해서는 안 됩니다. 혈액 선별 검사에는 차세대 시퀀싱, 핵산 검사, ELISA 등 다양한 기술이 사용되고 있습니다.

시장 역학

혈액 선별검사 증가

혈액 선별 검사는 귀중한 정보를 제공하고 특정 질병을 진단하기 위해 혈액 샘플에 대해 수행됩니다. 혈액 선별 검사 제품 출시 증가는 시장 성장의 중요한 원동력이 되고 있습니다. 또한 많은 주요 기업들이 새로운 혈액 선별 검사와 키트를 출시하여 시장 발전에 큰 역할을하고 있습니다.

예를 들어, 2023년 10월, Delfi Diagnostics는 혈액 기반 폐암 선별 검사를 출시했습니다. 이 검사는 더 편리한 탐지 방법을 제공하고 현재 표준보다 더 많은 사람들에게 도달 할 수 있도록하는 것을 목표로합니다.

또한 2023년 8월, 퀘스트 다이아그노스틱스는 미국에서 알츠하이머병의 AD-Detect 검사를 도입해 소비자들이 알츠하이머병 발병의 잠재적 위험을 평가할 수 있는 최초의 혈액 기반 바이오마커 검사로 출시할 수 있도록 했습니다.

또한, 세계 혈액 스크리닝 시장은 헌혈 증가와 같은 다양한 요인에 의해 주도되며, 감염성 질환의 발생률 증가가 예측 기간 동안 시장을 견인할 것으로 예상됩니다.

엄격한 규제 당국의 승인과 혈액 스크리닝 장비의 고비용

엄격한 규제 요건은 새로운 혈액 스크리닝 기술 및 검사의 승인과 채택을 지연시킬 수 있습니다. 또한 혈액 스크리닝 장비와 관련된 높은 비용은 시장 성장을 저해할 수 있습니다.

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 영향 분석

제5장 산업 분석

• Porter의 Five Forces 분석
• 공급망 분석
• 가격 분석
• 규제 분석
• DMI의 견해

제6장 COVID-19 분석

제7장 제품 유형별

• 기구
  • 직접 구매
  • 렌탈 구매
• 시약 및 키트
  • NAT 시약＆키트
    • 스탠다드＆컨트롤
    • 표지 및 탐지 시약
    • 효소 및 중합효소
    • 프로브 및 프라이머
    • 버퍼/뉴클레오티드/용액
  • ELISA 시약＆키트
    • 접합체(항원 또는 항체-접합체 효소)
    • 면역 흡착제
    • 컨트롤
    • 기질
    • 샘플 희석액 및 세정액
    • 기타 시약

제8장 기술별

• 차세대 시퀸싱(NGS)
• 차세대 시퀸싱(NGS)
  • 실시간 중합효소 연쇄반응(PCR)
  • 전사 매개 증폭(TMA)
• 효소 결합 면역 흡착 측정법(ELISA)
  • ELISA, 플랫폼별
    • 형광 면역측정법(FIA)
    • 화학 발광 면역측정법(CLIA)
    • 비색 면역측정법(CI)
  • ELISA, 세대별
    • 제1세대 ELISA
    • 제2세대 ELISA
    • 제3세대 ELISA
    • 제4세대 이상
• 웨스턴 블롯 어세이
• 신속 검사
• 기타

제9장 최종사용자별

• 병원
• 혈액은행
• 기타

제10장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 남미
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 호주
  • 기타 아시아태평양
• 중동 및 아프리카

제11장 경쟁 구도

• 경쟁 시나리오
• 시장 현황/점유율 분석
• M&A분석

제12장 기업 개요

• Bio-Rad Laboratories, Inc.
  • 기업 개요
  • 제품 포트폴리오와 설명
  • 재무 개요
  • 주요 발전
• Grifols
• Abbott Laboratories
• F. Hoffmann-La Roche
• Siemens Healthineers
• Biomerieux
• Thermo Fisher Scientific, Inc.
• Ortho Clinical Diagnostics, Inc.
• Becton, Dickinson, and Company
• Beckman Coulter(Danaher Corporation)

제13장 부록

영문목차

Overview

Blood screening tests are performed to identify infection signs in order to stop the distribution of contaminated blood and blood components for clinical use. A blood screening test is done to detect potential health disorders or diseases in people who do not have any symptoms of the disease.

Blood screening strategies are designed to assure the safety of blood units, but should not be used for notifying blood donors of reactive test results. Various technologies are used in blood screening tests which include next-generation sequencing, nucleic acid tests, and ELISA.

Market Dynamics

Increasing launches of blood screening tests

Blood screening tests are performed on a blood sample to provide valuable information and diagnose specific medical conditions. The increasing number of product launches for blood screening tests acts as a significant driver for market growth. Also, many significant companies play a major role in the advancements of the market by launching new blood screening tests and kits.

For instance, in October 2023, Delfi Diagnostics launched a blood-based lung cancer screening test. It aims to provide a more convenient detection method and one that's capable of reaching a greater number of people than the current standard.

Additionally, in August 2023, Quest Diagnostics introduced its AD-Detect test for Alzheimer's disease in the United States by making it the first blood-based biomarker test available for consumers to purchase and assess the potential risks of developing Alzheimer's disease.

Furthermore, the global blood screening market is driven by various factors like rising blood donations, and an increase in the incidence of infectious diseases is expected to drive the market in the forecast period.

The stringent regulatory approvals and high cost of blood screening equipment

Stringent regulatory requirements can slow the approval and adoption of new blood screening technologies or tests. Also, the high cost associated with blood screening equipment can hamper the market growth.

Segment Analysis

The global blood screening market is segmented based on product type, technology, end users, and region.

Reagents and kits accounted for approximately 48.4% of the market share

The anti-A, anti-B, and anti-A, B reagents are used in the red blood cell determination of the ABO blood group. They are used to determine the absence or presence of erythrocytic antigens A or B on the surface of human red blood cells. Reagents and kits are expected to hold the largest market share over the period forecast owing to the high requirement for reagents, kits, and product launches.

For instance, in June 2023, Sysmex launched an assay kit to identify Amyloid Beta (AB) accumulation in the brain that causes Alzheimer's disease by using a small amount of blood.

Additionally, in July 2021, Ortho Clinical Diagnostics launched its VITROS Immunodiagnostic Products IL-6 Reagent Pack which is the latest addition to Ortho's VITROS Critical Care blood screening menu.

Geographical Analysis

North America is expected to hold a significant position in the global blood screening market share

The global blood screening market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

North America has maintained a significant market proportion due to factors such as the rising blood transfusion rates, and product launches, this trend is anticipated to continue throughout the forecast period.

For instance, according to the American Red Cross, in the United States, an estimated 10,000 units of plasma, roughly 7,000 units of platelets, and 36,000 units of red blood cells are needed per day. In the United States, more than 21 million blood components are transfused annually.

Additionally, in September 2023, Oxford BioDynamics, Plc. Launched its 94% accurate EpiSwitch prostate screening blood test for men with prostate cancer risk.

COVID-19 Impact Analysis:

The COVID-19 pandemic has had a significant impact on the global blood screening market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatments, device launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the blood screening market is expected to be moderately affected over the forecast period.

Competitive Landscape

The major global players in the market include: Bio-Rad Laboratories, Inc., Grifols S.A, Abbott Laboratories, F. Hoffmann-La Roche, Siemens Healthineers, Biomerieux, Thermo Fisher Scientific, Inc., Ortho Clinical Diagnostics, Inc., Becton, Dickinson, and Company, Beckman Coulter (Danaher Corporation). Among others.

Key Developments

• In March 2023, H.U. Group Holdings Inc. introduced the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE G immunoassay systems. These CLEIA (chemiluminescent enzyme immunoassay) assays allow for the quantitative measurement of Neurofilament light (NfL) in human cerebrospinal fluid (CSF) and plasma.
• In June 2021, Grail launched the Galleri blood screening test which is a multi-cancer screening capable of detecting many cancers.

Why Purchase the Report?

• To visualize the global blood screening market segmentation based on product type, technology, end users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of blood screening market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global blood screening market report would provide approximately 61 tables, 58 figures, and 185 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Technology
• 3.3. Snippet by End User
• 3.4. Snippet by Region

4. Market Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing launches of blood screening tests
    • 4.1.1.2.
  • 4.1.2. Restraints
    • 4.1.2.1. The stringent regulatory approvals and high cost of blood screening equipment
    • 4.1.2.2.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Product Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.1.2. Market Attractiveness Index, By Product Type
• 7.2. Instruments*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Outright Purchase
  • 7.2.4. Rental Purchase
• 7.3. Reagents & Kits
  • 7.3.1. NAT Reagents & Kits
    • 7.3.1.1. Standards and Controls
    • 7.3.1.2. Labeling and Detection Reagents
    • 7.3.1.3. Enzymes and Polymerases
    • 7.3.1.4. Probes and Primers
    • 7.3.1.5. Buffers, Nucleotides, and Solutions
  • 7.3.2. ELISA Reagents & Kits
    • 7.3.2.1. conjugates (Antigen Or Antibody-Conjugated Enzyme)
    • 7.3.2.2. Immunosorbents
    • 7.3.2.3. Controls
    • 7.3.2.4. Substrates
    • 7.3.2.5. Sample Diluents and Wash Solutions
    • 7.3.2.6. Other Reagents

8. By Technology

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 8.1.2. Market Attractiveness Index, By Technology
• 8.2. Next-Generation Sequencing (NGS) *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Next-Generation Sequencing (NGS)
  • 8.3.1. Real-Time Polymerase Chain Reaction (PCR)
  • 8.3.2. Transcription-Mediated Amplification (TMA)
• 8.4. Enzyme-Linked Immunosorbent Assay (ELISA)
  • 8.4.1. ELISA, By Platform
    • 8.4.1.1. Fluorescence Immunoassay (FIA)
    • 8.4.1.2. Chemiluminescence Immunoassay (CLIA)
    • 8.4.1.3. Colorimetric Immunoassay (CI)
  • 8.4.2. ELISA, By Generation
    • 8.4.2.1. First-Generation ELISA
    • 8.4.2.2. Second-Generation ELISA
    • 8.4.2.3. Third-Generation ELISA
    • 8.4.2.4. Fourth-Generation & Above
• 8.5. Western Blot Assay
• 8.6. Rapid Tests
• 8.7. Others

9. By End Users

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 9.1.2. Market Attractiveness Index, By End Users
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Blood Banks
• 9.4. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. Australia
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Bio-Rad Laboratories, Inc.
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Grifols
• 12.3. Abbott Laboratories
• 12.4. F. Hoffmann-La Roche
• 12.5. Siemens Healthineers
• 12.6. Biomerieux
• 12.7. Thermo Fisher Scientific, Inc.
• 12.8. Ortho Clinical Diagnostics, Inc.
• 12.9. Becton, Dickinson, and Company
• 12.10. Beckman Coulter (Danaher Corporation)

LIST NOT EXHAUSTIVE.

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us